


medicament for the treatment of a medical condition selected from a diabetic condition, an inflammatory condition, macular degeneration, obesity, atherosclerosis, a condition associated with angiogenesis, or a proliferative disorder, by inhibiting CDK8 and/or CDK19 kinase activity in a subject.

[0002d] In a further aspect of the present disclosure, there is provided a compound of formula:




or a pharmaceutically acceptable salt thereof;

wherein:

m is 0, 1, 2, 3, or 4;

each instance of R^{6A} is independently halogen, $-\text{NO}_2$, $-\text{CN}$, $-\text{OR}^{6C}$, SR^{6C} , $\text{N}(\text{R}^{6C})_2$, $-\text{C}(=\text{O})\text{R}^{6C}$, $-\text{C}(=\text{O})\text{OR}^{6C}$, $-\text{C}(=\text{O})\text{N}(\text{R}^{6C})_2$, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and wherein each instance of R^{6C} is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to oxygen, a sulfur protecting group when attached to sulfur, or a nitrogen protecting group when attached to nitrogen, optionally when attached to N the two R^{6C} groups may be joined to form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring.

[0002e] In another aspect of the present disclosure, there is provided a compound of formula:



or a pharmaceutically acceptable salt thereof;


wherein:

m is 0, 1, 2, 3, or 4;

each instance of R^{6A} is independently halogen, $-\text{NO}_2$, $-\text{CN}$, $-\text{OR}^{6C}$, SR^{6C} , $\text{N}(\text{R}^{6C})_2$, $-\text{C}(=\text{O})\text{R}^{6C}$, $-\text{C}(=\text{O})\text{OR}^{6C}$, $-\text{C}(=\text{O})\text{N}(\text{R}^{6C})_2$, optionally substituted alkyl, optionally substituted

alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and wherein each instance of R^{6C} is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to oxygen, a sulfur protecting group when attached to sulfur, or a nitrogen protecting group when attached to nitrogen, optionally when attached to N the two R^{6C} groups may be joined to form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring.

[0002f] In yet another aspect of the present disclosure, there is provided a compound of formula:



or a pharmaceutically acceptable salt thereof;

wherein:

m is 0, 1, 2, 3, or 4;

R^3 is hydrogen or optionally substituted alkyl;

R^4 is hydrogen, halogen, optionally substituted alkyl, or $-\text{Si}(R^A)_3$;

R^5 is hydrogen, halogen, or optionally substituted alkyl;


each instance of --- , designated as (a) and (b) represents a single or double bond;

R^O is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, $-\text{C}(=\text{O})R^A$, $-\text{C}(=\text{O})OR^A$, $-\text{C}(=\text{O})\text{N}(R^A)_2$, or an oxygen protecting group.

each instance of R^A is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, carbonyl, silyl, an oxygen protecting group when attached to oxygen, a sulfur protecting group when attached to sulfur, or a nitrogen protecting group when attached to nitrogen; optionally when attached to N the two R^A groups may be joined to form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring;

each instance of R^{6A} is independently halogen, $-\text{NO}_2$, $-\text{CN}$, $-\text{OR}^{6C}$, SR^{6C} , $\text{N}(\text{R}^{6C})_2$, $-\text{C}(=\text{O})\text{R}^{6C}$, $-\text{C}(=\text{O})\text{OR}^{6C}$, $-\text{C}(=\text{O})\text{N}(\text{R}^{6C})_2$, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and wherein each instance of R^{6C} is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to oxygen, a sulfur protecting group when attached to sulfur, or a nitrogen protecting group when attached to nitrogen, optionally when attached to N the two R^{6C} groups may be joined to form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring.

[0002g] In a further aspect of the present disclosure, there is provided a compound of formula:



or a pharmaceutically acceptable salt thereof;

wherein:

m is 0, 1, 2, 3, or 4;

R^3 is hydrogen or optionally substituted alkyl;

R^4 is hydrogen, halogen, optionally substituted alkyl, or $-\text{Si}(\text{R}^A)_3$;

R^5 is hydrogen, halogen, or optionally substituted alkyl;

each instance of --- , designated as (a) and (b) represents a single or double bond;


R^0 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, $-\text{C}(=\text{O})\text{R}^A$, $-\text{C}(=\text{O})\text{OR}^A$, $-\text{C}(=\text{O})\text{N}(\text{R}^A)_2$, or an oxygen protecting group.

each instance of R^A is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, carbonyl, silyl, an oxygen protecting group when attached to oxygen, a sulfur protecting group when attached to sulfur, or a nitrogen protecting group when attached

to nitrogen; optionally when attached to N the two R^A groups may be joined to form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring;


each instance of R^{6A} is independently halogen, $-\text{NO}_2$, $-\text{CN}$, $-\text{OR}^{6C}$, SR^{6C} , $\text{N}(\text{R}^{6C})_2$, $-\text{C}(=\text{O})\text{R}^{6C}$, $-\text{C}(=\text{O})\text{OR}^{6C}$, $-\text{C}(=\text{O})\text{N}(\text{R}^{6C})_2$, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and wherein each instance of R^{6C} is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to oxygen, a sulfur protecting group when attached to sulfur, or a nitrogen protecting group when attached to nitrogen, optionally when attached to N the two R^{6C} groups may be joined to form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring.

[0002h] In another aspect of the present disclosure, there is provided a compound of Formula:




or a pharmaceutically acceptable salt thereof.

[0002i] In yet another aspect of the present disclosure, there is provided a pharmaceutical composition comprising compound:



or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.


[0002j] In a further aspect of the present disclosure, there is provided use of a compound:



or a pharmaceutically acceptable salt optionally in a pharmaceutical composition thereof for the manufacture of a medicament for the treatment of a medical condition selected from a diabetic condition, an inflammatory condition, macular degeneration, obesity, atherosclerosis, a condition associated with angiogenesis, or a proliferative disorder, by inhibiting CDK8 and/or CDK19 kinase activity in a subject.


[0002k] In another aspect of the present disclosure, there is provided a compound as defined herein, or a pharmaceutically acceptable salt, optionally in a pharmaceutical composition, for use in therapy.

[0002l] In yet another aspect of the present disclosure, there is provided a compound:



or a pharmaceutically acceptable salt optionally in a pharmaceutical composition thereof for use in therapy.

[0002m] In a further aspect of the present disclosure, there is provided a compound of Formula:



or a pharmaceutically acceptable salt or quaternary amine salt thereof;

wherein:

n is 0, 1, or 2;

m is 0, 1, 2, 3, or 4;

G is -O-, -S-, -NH-, -NR⁷-, -CH₂-, -CH(R⁷)-, or -C(R⁷)₂-;

each instance of R⁷ is independently amino, hydroxyl, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, substituted amino, substituted hydroxyl, thiol, substituted thiol, carbonyl, sulfonyl, sulfinyl, or a nitrogen protecting group when attached to a nitrogen atom;

optionally wherein two R⁷ groups are joined to form an optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl ring, or an oxo (=O) group;

each instance of R^{6A} is independently halogen, -NO₂, -CN, -OR^{6C}, SR^{6C}, N(R^{6C})₂, -C(=O)R^{6C}, -C(=O)OR^{6C}, -C(=O)N(R^{6C})₂, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and

wherein each instance of R^{6C} is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to oxygen, a sulfur protecting group when attached to sulfur, or a nitrogen protecting group when attached to nitrogen, optionally when attached to N the two R^{6C} groups may be joined to form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring.


[0003] Provided herein are new cortistatin analogs of Formula (A), (B), and (C), and pharmaceutically acceptable salts, quaternary amine salts, and N-oxides thereof, synthesized, in part, by reductive amination of a ketone of Formula (B) to provide the aminated product of Formula (A), as depicted in *Scheme 1*, optionally *via* an imine intermediate of Formula (C).

[0004] Further provided are new cortistatin analogs prepared by reduction of the ketone of Formula (B) to provide a C3-hydroxyl compound of Formula (D). Still yet further provided is a compound of Formula (E), prepared by substitution of the compound of Formula (D). Such compounds may also be converted to a compound of Formula (A) upon treatment with an amine under suitable conditions.

[0005] It has been surprisingly found that the *beta* isomers of Formula (A), referred to as Formula (A-1), have been found to be equipotent, or more potent, than cortistatin A at inhibiting CDK8 kinase activity and the proliferation of AML cells, and it has also been found that the corresponding *alpha* isomers of Formula (A), referred to as Formula (A-2), are

optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to oxygen, a sulfur protecting group when attached to sulfur, or a nitrogen protecting group when attached to nitrogen, optionally when attached to N the two R^{6C} groups may be joined to form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring.

3. The compound of claim 2, wherein m and n are independently 0, 1, or 2.
4. The compound of claim 3, wherein m is 0 and n is 1.
5. The compound of claim 4, wherein G is $-\text{CH}_2-$, $-\text{CH}(R^7)-$, or $-\text{C}(R^7)_2-$, and each instance of R^7 is independently hydroxyl, amino, or halogen.
6. The compound of claim 5, wherein G is $-\text{CH}(R^7)-$ and each instance of R^7 is hydroxyl.
7. The compound of claim 3 wherein m is 0 and n is 0.
8. The compound of claim 7, wherein G is $-\text{CH}(R^7)-$ and R^7 is amino.
9. The compound of claim 1 of Formula:



or a pharmaceutically acceptable salt or quaternary amine salt thereof;
wherein:

n is 0, 1, or 2;

m is 0, 1, 2, 3, or 4;

G is $-\text{NH}-$, $-\text{NR}^7-$, $-\text{CH}_2-$, $-\text{CH}(R^7)-$, or $-\text{C}(R^7)_2-$;

each instance of R^7 is independently amino, hydroxyl, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally

substituted heteroaryl, substituted amino, substituted hydroxyl, thiol, substituted thiol, carbonyl, sulfonyl, sulfinyl, or a nitrogen protecting group when attached to a nitrogen atom;

optionally wherein two R^7 groups are joined to form an optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl ring, or an oxo (=O) group;

each instance of R^{6A} is independently halogen, $-NO_2$, $-CN$, $-OR^{6C}$, SR^{6C} , $N(R^{6C})_2$, $-C(=O)R^{6C}$, $-C(=O)OR^{6C}$, $-C(=O)N(R^{6C})_2$, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and

wherein each instance of R^{6C} is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to oxygen, a sulfur protecting group when attached to sulfur, or a nitrogen protecting group when attached to nitrogen, optionally when attached to N the two R^{6C} groups may be joined to form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring.

10. The compound of claim 9, wherein m and n are independently 0, 1, or 2.

11. The compound of claim 10, wherein m and n are 0.

12. The compound of claim 11, wherein G is $-CH_2-$, $-CH(R^7)-$, or $-C(R^7)_2-$, and R^7 is hydroxyl, amino, or halogen..


13. The compound of claim 12, wherein G is $-CH(R^7)-$, and R^7 is hydroxyl.

14. The compound of claim 12, wherein G is $-CH(R^7)-$, and R^7 is amino.

15. A compound of Formula:

and pharmaceutically acceptable salts thereof.

20. The compound of claim 15, wherein the compound is selected from the group consisting of:




and pharmaceutically acceptable salts thereof.

21. A pharmaceutical composition comprising a compound according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable excipient.
22. Use of a compound according to any one claims 1 to 20, or a pharmaceutically acceptable salt, in the manufacture of a medicament for the treatment of a medical condition selected from a diabetic condition, an inflammatory condition, macular degeneration, obesity, atherosclerosis, a condition associated with angiogenesis, or a proliferative disorder, by inhibiting CDK8 and/or CDK19 kinase activity in a subject.
23. The use of claim 22, wherein the condition is a diabetic condition, macular degeneration, obesity, atherosclerosis, a condition associated with angiogenesis, or a proliferative disorder.
24. The use of claim 23, wherein the condition is a proliferative disorder and the proliferative disorder is primary myelofibrosis (PMF).
25. The use of claim 22, wherein the condition is a cancer.
26. The use of claim 25, wherein the cancer is a solid tumor or a hematopoietic cancer.
27. The use of claim 26, wherein the cancer is a hematopoietic cancer.
28. The use of any one of claims 22 to 27, wherein the subject is a human.

alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and

wherein each instance of R^{6C} is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to oxygen, a sulfur protecting group when attached to sulfur, or a nitrogen protecting group when attached to nitrogen, optionally when attached to N the two R^{6C} groups may be joined to form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring.

31. A compound of formula:



or a pharmaceutically acceptable salt thereof;

wherein:

m is 0, 1, 2, 3, or 4;

R^3 is hydrogen or optionally substituted alkyl;


R^4 is hydrogen, halogen, optionally substituted alkyl, or $-\text{Si}(\text{R}^A)_3$;

R^5 is hydrogen, halogen, or optionally substituted alkyl;

each instance of ----, designated as (a) and (b) represents a single or double bond;

R^O is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, $-\text{C}(=\text{O})\text{R}^A$, $-\text{C}(=\text{O})\text{OR}^A$, $-\text{C}(=\text{O})\text{N}(\text{R}^A)_2$, or an oxygen protecting group.

each instance of R^A is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, carbonyl, silyl, an oxygen protecting group when attached to oxygen, a sulfur protecting group when attached to sulfur, or a nitrogen protecting group when attached to nitrogen; optionally when



or a pharmaceutically acceptable salt thereof;

wherein:

m is 0, 1, 2, 3, or 4;

R^3 is hydrogen or optionally substituted alkyl;

R^4 is hydrogen, halogen, optionally substituted alkyl, or $-\text{Si}(R^A)_3$;

R^5 is hydrogen, halogen, or optionally substituted alkyl;

each instance of , designated as (a) and (b) represents a single or double bond;

R^O is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, $-\text{C}(=\text{O})R^A$, $-\text{C}(=\text{O})\text{OR}^A$, $-\text{C}(=\text{O})\text{N}(R^A)_2$, or an oxygen protecting group.


each instance of R^A is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, carbonyl, silyl, an oxygen protecting group when attached to oxygen, a sulfur protecting group when attached to sulfur, or a nitrogen protecting group when attached to nitrogen; optionally when attached to N the two R^A groups may be joined to form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring;

each instance of R^{6A} is independently halogen, $-\text{NO}_2$, $-\text{CN}$, $-\text{OR}^{6C}$, SR^{6C} , $\text{N}(R^{6C})_2$, $-\text{C}(=\text{O})R^{6C}$, $-\text{C}(=\text{O})\text{OR}^{6C}$, $-\text{C}(=\text{O})\text{N}(R^{6C})_2$, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and

wherein each instance of R^{6C} is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to oxygen, a sulfur protecting group when attached to sulfur, or a nitrogen protecting group when attached to nitrogen, optionally when attached to N


the two R^{6C} groups may be joined to form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring.

34. A compound of Formula:




or a pharmaceutically acceptable salt thereof.

35. A pharmaceutical composition comprising compound:



or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

36. Use of a compound:



or a pharmaceutically acceptable salt optionally in a pharmaceutical composition thereof for the manufacture of a medicament for the treatment of a medical condition selected from a diabetic condition, an inflammatory condition, macular degeneration, obesity, atherosclerosis, a condition associated with angiogenesis, or a proliferative disorder, by inhibiting CDK8 and/or CDK19 kinase activity in a subject.

37. The use of claim 36, wherein the condition is a diabetic condition, macular degeneration, obesity, atherosclerosis, a condition associated with angiogenesis, or a proliferative disorder.

38. The use of claim 37, wherein the condition is a proliferative disorder and the proliferative disorder is primary myelofibrosis (PMF).


39. The use of claim 36, wherein the condition is a cancer.

40. The use of claim 39, wherein the cancer is a solid tumor or a hematopoietic cancer.

41. The use of claim 40, wherein the cancer is a hematopoietic cancer.

42. The use of any one of claims 36 to 41, wherein the subject is a human.


43. The compound of claim 30, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

44. A compound according to any one claims 1 to 20, or a pharmaceutically acceptable salt, optionally in a pharmaceutical composition, for use in therapy.

45. A compound:



or a pharmaceutically acceptable salt optionally in a pharmaceutical composition thereof for use in therapy.

46. The use of claim 26, wherein the cancer is a hematopoietic cancer, and the hematopoietic cancer is selected from multiple myeloma, lymphoma, and acute myelocytic leukemia (AML).

47. The use of claim 26, wherein the cancer is a hematopoietic cancer, and the hematopoietic cancer is leukemia.

48. The use of claim 26, wherein the cancer is a hematopoietic cancer, and the hematopoietic cancer is acute myelocytic leukemia (AML).

49. The use of claim 26, wherein the cancer is a hematopoietic cancer, and the hematopoietic cancer is acute lymphocytic leukemia (ALL).

50. The use of claim 26, wherein the cancer is a hematopoietic cancer, and the hematopoietic cancer is chronic lymphocytic leukemia (CLL).

51. The use of claim 40, wherein the cancer is a hematopoietic cancer, and the hematopoietic cancer is selected from multiple myeloma, lymphoma, and acute myelocytic leukemia (AML).

52. The use of claim 40, wherein the cancer is a hematopoietic cancer, and the hematopoietic cancer is leukemia.

53. The use of claim 40, wherein the cancer is a hematopoietic cancer, and the hematopoietic cancer is acute myelocytic leukemia (AML).

54. The use of claim 40, wherein the cancer is a hematopoietic cancer, and the hematopoietic cancer is acute lymphocytic leukemia (ALL).

55. The use of claim 40, wherein the cancer is a hematopoietic cancer, and the hematopoietic cancer is chronic lymphocytic leukemia (CLL).

56. The use of any one of claims 46 to 55, wherein the subject is a human.